Catherine Stehman-Breen

Affiliate Associate Professor, Epidemiology



MD Medicine, University of Chicago, 1990
MS Epidemiology, University of Washington, 1996
BS Biology, Colby College, 1985



51 Gray St
Boston, MA 02116
View Website »


My academic career focuses on clinical research in bone, kidney and neurologic diseases. The goal of these clinical trial programs is to bring innovative therapeutics to people with serious illnesses. My areas of focus are osteoporosis, hyperparathyroidism in kidney disease and migraine.

Catherine received her medical degree from University of Chicago in 1990. She completed her residency and fellowship training at the University of Washington where she also received a Masters of Science degree in Epidemiology. She spent six years as a Faculty member in the Division of Nephrology at University of Washington. Her primary responsibilities included managing the Clinical Research Training Program and the development of the Epidemiology and Clinical Trials Research Program. Her research focused on bone and cardiovascular disease in renal disease patients. Catherine joined Amgen in 2003 where she became the Global Development Leader for Aranesp and Epogen. She became the Therapeutic Area Head for Bone, Nephrology and Neuroscience and was responsible for clinical programs related to bone loss, nephrology and several neuroscience indications. In 2015, she became the therapeutic area head for pain at Regeneron Pharmaceuticals. She is now the head of Clinical Operations.

Research Interests

• Fasinumab: A monoclonal antibody to nerve growth factor and a potential treatment for chronic pain

The epidemiology of bone disease in patients with Duchenne muscular dystrophy.

Recent Publications (PubMed)

Design and methods of a postmarketing pharmacoepidemiology study assessing long-term safety of Prolia® (denosumab) for the treatment of postmenopausal osteoporosis.
(2013 Oct)
Pharmacoepidemiol Drug Saf 22(10): 1107-14
Xue F, Ma H, Stehman-Breen C, Haller C, Katz L, Wagman RB, Critchlow CW, Denosumab Global Safety Assessment Team

Effects of denosumab on fracture and bone mineral density by level of kidney function.
(2011 Aug)
J Bone Miner Res 26(8): 1829-35
Jamal SA, Ljunggren O, Stehman-Breen C, Cummings SR, McClung MR, Goemaere S, Ebeling PR, Franek E, Yang YC, Egbuna OI, Boonen S, Miller PD

Chronic kidney disease and the risk of end-stage renal disease versus death.
(2011 Apr)
J Gen Intern Med 26(4): 379-85
Dalrymple LS, Katz R, Kestenbaum B, Shlipak MG, Sarnak MJ, Stehman-Breen C, Seliger S, Siscovick D, Newman AB, Fried L

Effect of darbepoetin alfa administered once monthly on maintaining hemoglobin levels in older patients with chronic kidney disease.
(2008 Jun)
Am J Geriatr Pharmacother 6(2): 49-60
Silver MR, Agarwal A, Krause M, Lei L, Stehman-Breen C

Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients.
(2008 Jul)
Clin J Am Soc Nephrol 3(4): 1077-83
Kilpatrick RD, Critchlow CW, Fishbane S, Besarab A, Stehman-Breen C, Krishnan M, Bradbury BD

Show complete publication list

In the News

No news articles at this time.